Vatelizumab Setback Dulls Glenmark's Q2 Growth
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticals Ltd reported overall growth in the second quarter ended September, but Sanofi's decision to end development of the Indian firm's monoclonal antibody, vatelizumab (GBR-500), took some sheen off its good run.